In this review, we briefly introduce the drug utilization, effectiveness, and safety of the most used anti-TNFα originators (infliximab and adalimumab), and elaborate on the efficacy and safety of these biosimilars in IBD. This evidence concerns the gene TNF and inflammatory bowel disease.